Jazz Pharmaceuticals

Jazz Pharmaceuticals

Overview

Jazz Pharmaceuticals plc formed with a merger of Jazz Pharmaceuticals, Inc. and Azur Pharma plc, is a biopharmaceutical company based in Ireland which was founded in 2003.

What are the annual sales of Jazz pharmaceuticals?

• In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales while in 2018, 75% of net product sales were generated by one product, Xyrem.
• In the fourth quarter of 2021, 59% of net product sales were generated from products that we launched or acquired since 2019, including Xywav, Zepzelca, Epidiolex, Sunosi, Sativex and Rylaze.

What are the sleep / neuroscience products of Jazz?

• Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution, a product approved by the U.S. Food and Drug Administration, or FDA, in July 2020 and launched in the U.S. in November 2020 for the treatment of cataplexy or [[excessive daytime sleepiness[[.
• Xyrem (sodium oxybate) oral solution, a product approved by FDA and distributed in the U.S. for the treatment of both cataplexy and EDS in patients seven years of age and older with narcolepsy;
• Epidiolex® (cannabidiol) oral solution, a product approved by FDA and launched in the U.S. in 2018 by GW Pharmaceuticals plc, or GW, and currently indicated for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex, or TSC, in patients one year of age or older; in Europe (where it is marketed as Epidyolex®) and other markets, it is approved for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome, in conjunction with clobazam (EU and Great Britain only), in patients 2 years of age and older and for adjunctive treatment of seizures associated with TSC in patients 2 years of age and older;
• Sunosi® (solriamfetol), a product approved by FDA and marketed in the U.S., Canada, Europe and Great Britain to improve wakefulness in adult patients with EDS associated with narcolepsy or obstructive sleep apnea, or OSA; and
• Sativex® (nabiximols) oral solution, a product approved and marketed in the U.K., Canada and other markets as treatment for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis, or MS, who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity-related symptoms during an initial trial of therapy.

What are the oncology products of Jazz?

• Zepzelca® (lurbinectedin), a product approved by FDA in June 2020 and launched in the U.S. in July 2020 for the treatment of adult patients with metastatic small cell lung cancer, or SCLC, with disease progression on or after platinum-based chemotherapy; in Canada, Zepzelca was approved in September 2021 for the treatment of adults with Stage III or metastatic SCLC, who have progressed on or after platinum-containing therapy;
• Rylaze™ (recombinant Erwinia asparaginase), a product approved by FDA in June 2021 and launched in the U.S. in July 2021 for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia, or ALL, or lymphoblastic lymphoma, or LBL, in adults and pediatric patients who have developed hypersensitivity to E. coli-derived asparaginase;
• Vyxeos® (daunorubicin and cytarabine) liposome for injection, a product approved in the U.S., Canada, Europe and Great Britain (marketed as Vyxeos® liposomal in Europe and Great Britain) for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia, or t-AML, or AML with myelodysplasia-related changes (AML-MRC). An expanded indication was granted in the U.S. for the treatment of newly diagnosed t-AML or AML-MRC in pediatric patients aged 1 year and older; and
• Defitelio® (defibrotide sodium), is a product approved in the U.S. and Brazil for the treatment of hepatic veno-occlusive disease, or VOD, with renal or pulmonary dysfunction following hematopoietic stem cell transplantation, or HSCT, and in Japan for the treatment of hepatic sinusoidal obstruction syndrome (hepatic-veno occlusive disease).

When did Jazz pharmaceuticals acquire GW Pharmaceuticals?

• In May 2021, Jazz acquired GW Pharmaceuticals plc, or GW with a total consideration paid by us for the entire issued share capital of GW was $7.2 billion which closed on May 5, 2021.

What is the acquisition history of Jazz Pharmaceuticals?

According to Wikipedia, here is the acquisition history of Jazz

• Jazz Pharmaceuticals
  • Jazz Pharmaceuticals PLC
    • Jazz Pharmaceuticals, Inc. (Merged 2011)
    • Azur Pharma PLC (Merged 2011)
  • EUSA Pharma (Acq 2012)
  • Gentium SpA (Acq 2014)
  • Alizé Pharma II (Acq 2016)
  • Celator Pharmaceuticals (Acq 2016)
  • Cavion Inc. (Acq 2019)
  • GW Pharmaceuticals (Acq 2021)

What products are under development by Jazz?

• Epidiolex - Phase 3 clinical trial of Epidiolex for the treatment of Epilepsy with Myoclonic-Atonic Seizures, or EMAS, also known as Doose syndrome, to start in the first half of 2022.
• Nabiximols - three ongoing Phase 3 clinical trials in multiple sclerosis (MS)-related spasticity.
• JZP150 - JZP150 is a fatty acid amide hydrolase, or FAAH, inhibitor program for the potential treatment of post-traumatic stress disorder, or PTSD, and associated symptoms in Phase 2 clinical trials Zepzelca in phase 3 pivotal clinical trial

Other products

• Rylaze IV dosing
• Vyxeos
• CombiPlex Platform

What are the corporate locations of Jazz?

The corporate headquarters for Jazz Pharmaceuticals are located in Dublin, Ireland, and our U.S. operations are located in Palo Alto, California, Carlsbad, California and Philadelphia, Pennsylvania.

This article is a stub. You can help WikiMD by registering to expand it. Editing is available only to registered and verified users. WikiMD is a comprehensive, free health & wellness encyclopedia.